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Abstract
Background—The clinical and microbiological characteristics of nontyphoidal Salmonella 
(NTS) meningitis in South Africa, where human immunodeficiency virus (HIV) prevalence is high 
(approximately 15% in persons ≥15 years of age), were reviewed.
Methods—From 2003 through 2013, 278 cases were identified through national laboratory-based 
surveillance. Clinical information (age, sex, outcome, Glasgow Coma Scale [GCS], and HIV 
status) was ascertained at selected sites. Isolates were serotyped; susceptibility testing and 
multilocus sequence typing on Salmonella enterica serovar Typhimurium isolates was performed. 
Multivariable logistic regression was used to determine factors associated with mortality outcome, 
using Stata software, version 13.
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Results—Where age was ascertained, 139 of 256 (54.3%) patients were <15 years. Males 
represented 151 of 267 (56.6%). Mortality outcome was recorded for 112 of 146 (76.7%) 
enhanced surveillance patients; 53 of 112 (47.3%) died. Death was associated with GCS ≤13 
(adjusted odds ratio [OR], 18.7; 95% confidence interval [CI], 3.0–118.5; P = .002) on 
multivariable analysis. Where data were available, all 45 patients aged >15 years were HIV 
infected, compared with 24 of 46 (52.2%) patients aged <5 years. Neonates were less likely to be 
HIV infected than infants aged 2–12 months (OR, 4.8; 95% CI, 1.1–21.1; P = .039).
Salmonella—Typhimurium represented 106 of 238 (44.5%) serotyped isolates: 65 of 95 (68.4%) 
were ST313 vs ST19, respectively, and significantly associated with HIV-infected patients (P = .
03) and multidrug resistance (OR, 6.6; 95% CI, 2.5–17.2; P < .001).
Conclusions—NTS meningitis in South Africa is highly associated with HIV in adults, with 
neonates (irrespective of HIV status), and with Salmonella Typhimurium ST313. GCS is the best 
predictor of mortality: early diagnosis and treatment are critical. Focused prevention requires 
further studies to understand the sources and transmission routes.
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Bacterial meningitis in Africa remains an important disease with a high associated mortality 
[1–7]. Meningitis in human immunodeficiency virus (HIV)–infected persons is frequently 
associated with cryptococcosis, tuberculosis, and Streptococcus pneumoniae, Haemophilus 
influenzae type b (Hib), and Neisseria meningitidis [3, 4, 8–12]. Numerous other pathogens 
have been described as a cause of meningitis among HIV-infected persons [1, 7, 9, 12, 13]. 
Nontyphoidal Salmonella (NTS) is emerging as a significant meningeal pathogen among 
HIV-infected persons, following the decline in incidence of S. pneumoniae and Hib with the 
introduction of pneumococcal conjugate and Hib conjugate vaccines [1, 6, 9, 12–14]. In 
previous series, in adults from South African institutions, NTS meningitis represented 16% 
of acute bacterial meningitis cases among HIV-infected patients [7]. An estimated 8% of all 
meningitis cases for which a microbiological diagnosis was made was attributed to acute 
bacterial meningitis [15]. NTS meningitis was not reported in pediatric series [16, 17].
The association between HIV and invasive NTS infections, including meningitis, was 
described early in the AIDS epidemic [18]. Case reports of adults with NTS meningitis 
frequently describe an association with HIV [7, 18–20], although other immunosuppressive 
conditions have been described [21–23]. Molyneux et al described NTS meningitis in a 
cohort of 105 Malawian children, aged between 2 months and 16 years, over a 10-year 
period [2]. Approximately half were HIV infected, and 12.4% were infected with malaria; 
mortality rates were >50% [2]. There are rare reports of NTS meningitis in previously 
healthy individuals [24], suggesting that comorbidity is common, but not an absolute 
prerequisite to infection.
A meta-analysis of published African studies suggests that Salmonella bacteremia accounts 
for 21.4% of all bacteremias [25], with an incidence rate of 227 per 100 000 [26]. In 
contrast, Salmonella meningitis accounted for <10% of all-cause meningitis (incidence rate 
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of 20/100 000) in Malawian patients in 2012 [6], suggesting approximately 1% of NTS 
bacteremias results in meningitis. Salmonella enterica serovars Typhimurium and Enteritidis 
account for 65.2% and 33.1% of all invasive NTS infections, respectively [25], and similar 
observations have been made regarding the frequency with which these serovars occur in 
NTS meningitis [2]. In the past 30 years, the emergence of invasive Salmonella 
Typhimurium ST313, a sequence type associated with the African AIDS epidemic, has been 
highlighted [27, 28].
We describe the clinical and microbiological data associated with a series of patients 
presenting with NTS meningitis in South Africa, a country that is largely malaria-free, with 
high HIV prevalence affecting approximately 15% of the population ≥15 years of age [29], 
to better understand the association with HIV, potential predisposing conditions, and the role 
of Salmonella Typhimurium ST313.
METHODS
Case Definition
National active laboratory-based surveillance for invasive salmonellosis, defined as the 
isolation of NTS from a normally sterile body site, including Salmonella meningitis, was 
performed by the Centre for Enteric Diseases (CED) of the National Institute for 
Communicable Diseases in South Africa from 2003 through 2013, as previously described 
[30]. A case of NTS meningitis was defined as any patient from whom NTS was isolated 
from cerebrospinal fluid (CSF). A nosocomial infection was defined as NTS meningitis 
infection in a patient in whom the diagnosis of meningitis was made ≥48 hours after the 
patient had been admitted to a medical or long-term-care facility. We used the annualized 
South African population from 2003 to 2013, which increased from 45.80 million to 52.98 
million over the period, to calculate incidence (http://www.statssa.gov.za/publications).
All diagnostic microbiology laboratories in South Africa were requested to submit 
Salmonella isolates from patients fulfilling the case definition, for serotyping and 
susceptibility testing, supplemented by audits from 2005 to identify isolates not received by 
the reference laboratory. Additional clinical information was collected on cases at 24 
sentinel hospitals in 9 provinces through the Group for Enteric, Respiratory and Meningeal 
Disease Surveillance in South Africa network, a national surveillance system sharing 
resources to monitor diseases of public health importance. This included data on HIV status, 
other immunosuppressive conditions, admission and discharge dates, antibiotic exposure, 
timing of meningitis diagnosis (number of hours after patient admission), and disease 
outcome.
Laboratory Characterization
All Salmonella isolates received were serotyped by CED according to established protocols 
(Mast Group, Merseyside, United Kingdom; Bio-Rad, Marnes-la-Coquette, France; Remel, 
Kent, United Kingdom; Statens Serum Institut, Copenhagen, Denmark). Minimum 
inhibitory concentrations (MICs) were determined for the following antimicrobials: 
ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole (cotrimoxazole), tetracycline, 
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ciprofloxacin, ceftriaxone, and ceftazidime, using Etest strips according to the 
manufacturer’s instructions (bioMérieux, Marcy-l’Étoile, France). Multidrug resistance was 
defined as resistance to ≥3 of these antimicrobials. Production of extended-spectrum β-
lactamase was tested for using the Mast Laboratories double disk method, according to the 
manufacturer’s instructions (Mast Diagnostics, Bootie, England).
Genotypic Characterization of Salmonella Typhimurium
Genotyping of Salmonella Typhimurium isolates was performed using multilocus sequence 
typing (MLST), as described at the Salmonella MLST database (http://mlst.warwick.ac.uk/
mlst/dbs/Senterica), including DNA sequencing analysis of the following 7 housekeeping 
genes: aroC, dnaN, hemD, hisD, purE, sucA, and thrA. DNA sequencing was performed 
using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, 
California) and an Applied Biosystems 3500 Genetic Analyzer. DNA sequences were 
collated and analyzed using the DNASTAR Lasergene (version 8.0) software (DNASTAR, 
Inc, Madison, Wisconsin), followed by analysis at the Salmonella MLST database, where 
allele numbers and a MLST sequence type (ST) were assigned.
Ethical Approval
Ethical approval for this study was granted by the Human Research Ethics Committee of the 
University of the Witwatersrand (M110601).
Statistical Analysis
Variables analyzed included age, sex, HIV status, Glasgow Coma Scale (GCS), nosocomial 
infection, cotrimoxazole prophylaxis, use of antiretrovirals (ARVs), CD4+ count, other 
comorbid conditions, isolation of Salmonella Typhimurium or multidrug-resistant 
Salmonella, and Salmonella sequence type. Clinically relevant groupings were created for 
continuous variables, to aid interpretation of results. Univariate and multivariate logistic 
regression were used to determine factors associated with mortality. Multivariate analysis 
using a manual forward stepwise progression was used, with a cutoff of P < .1 for the 
univariate analysis, dropping nonsignificant factors. Model fit was assessed by using the 
Hosmer–Lemeshow goodness-of-fit test. Analysis was performed using Stata version 13 
(StataCorp, College Station, Texas). Two-sided P values of <.05 were considered significant 
throughout. Due to the nature of the study, important variables had missing data. For both 
univariate and multivariate analyses, a complete case analysis was conducted in which 
patients with missing data were excluded from the analysis.
RESULTS
Cumulative Data
Figure 1 summarizes case numbers, including relevant clinical and microbiological data 
pertaining to these. We identified a total of 278 cases of laboratory-confirmed NTS 
meningitis in South African hospitals from 2003 through 2013, representing 3.3% of all 
invasive salmonellosis (Figure 1). Bimodal peaks of disease incidence were observed in 
children <5 years of age and adults >15 years of age (Figure 2A). NTS was isolated from the 
CSF only in 196 (70.5%) patients; NTS was additionally isolated from blood, stool, or other 
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body sites of 82 (29.5%) patients. The average incidence of NTS meningitis during the 
period was 5 per 10 000 000 per year. Clinical data are summarized in Table 1.
Clinical Data
Additional clinical information was available from 146 (52.5%) patients with NTS 
meningitis: 112 had a known outcome (76.7%) (Figure 1), and 111 (99.1%) and 82 (73.2%) 
had an available age and HIV status, respectively. Sex was recorded in 267 patients: 151 of 
267 (56.6%) were male. Table 2 summarizes clinical risk factors for mortality. Nineteen of 
58 (32.8%) children aged <15 years died, compared with 34 of 53 (64.2%) patients aged ≥15 
years (P = .001; Table 2, Figure 2B). HIV status was recorded for 92 of 146 (63.0%) 
patients; 70 (76.1%) were HIV infected (Figure 2C). Among patients with recorded age and 
HIV status, all 45 patients aged ≥15 years were HIV infected, compared with 24 of 46 
(52.2%) patients aged <5 years (Figure 2C). Children aged between 5 and 15 years had no 
outcome or HIV data recorded. Nine of 11 (81.9%) infants aged >1 year for whom data were 
available had a history of HIV exposure at birth.
Neonates were significantly less likely to be HIV infected than infants aged between 2 
months and 1 year (3/12 [25.0%] vs 19/31 [61.3%]; odds ratio [OR], 4.8; 95% confidence 
interval [CI], 1.1–21.1; P = .039); however, there was no difference in mortality between the 
2 groups (7/18 [38.9%] vs 12/38 [31.6%]; OR, 0.7; 95% CI, .2–2.3; P = .590). Nosocomial 
NTS meningitis was diagnosed in 13 of 118 (11.0%) patients for whom admission dates 
were available.
The length of hospital stay varied between 0 and 77 days (median of 12 days). Cases were 7 
times more likely to die within the initial 10 days of their hospital stay (OR, 7.1; 95% CI, 
3.1–16.4; P < .001). There was no significant association between nosocomial vs 
community-acquired infections and mortality (Table 2).
CD4+ cell counts were available for 33 of 146 (22.6%) patients. A CD4+ count <200 
cells/μL was not significantly associated with mortality (Table 2). Whether the HIV-infected 
patients received ARVs was recorded for 41 patients with NTS meningitis; 10 (24.4%) 
received ARVs at the time of diagnosis of NTS meningitis. There was no significant effect 
on the mortality between HIV-infected persons on ARVs and those not on ARVs (P = .7; 
Table 2).
The GCS was recorded for 43 patients: 7 of 43 (16.3%) had a GCS ≤13. For the 35 (81.4%) 
patients with GCS recorded for whom HIV status was known, 9 of 10 HIV-uninfected 
patients had a GCS >13 (90.0%), compared with 18 of 25 (72.0%) HIV-infected patients. 
Multivariable analysis confirmed that mortality was associated with a GCS ≤13 (adjusted 
OR, 18.7; 95% CI, 3.0–118.5; P = .002; Table 2). The Hosmer–Lemeshow goodness-of-fit 
test confirmed the fitness of the model (χ2 = 0.04, P = .8411).
Comorbidities potentially associated with NTS meningitis were recorded in 45 of 124 
(36.2%) patients. Laboratory-confirmed cryptococcal meningitis was diagnosed in 3 of 45 
(6.7%); 5 of 45 (11.1%) had a history of head injury; and 29 of 45 (64.4%) were receiving 
therapy for tuberculosis or had a history of active tuberculosis, but the site of tuberculosis 
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infection was not stated (ie, pulmonary vs extrapulmonary or central nervous system 
infection). One HIV-uninfected 3-month-old infant receiving treatment for tuberculosis had 
a GCS of 1. No patients were coinfected with other etiological agents of acute bacterial 
meningitis (S. pneumoniae, N. meningitidis, or Hib). None of the patients had malaria.
In addition, 81 of 146 (55.5%) patients had data on cotrimoxazole prophylaxis. 
Cotrimoxazole prophylaxis was not significantly associated with outcome (P = .3; Table 2). 
Individual patient records suggested that all patients received appropriate antimicrobial 
therapy for NTS meningitis on admission or were changed to appropriate antimicrobial 
therapy once susceptibility data were available for the Salmonella isolated from the patients’ 
CSF.
Microbiological Data
Microbiological characterization was undertaken on 247 of 278 (88.8%) isolates. Salmonella 
Typhimurium predominated (Table 3).
Patient outcome information was available for 111 of 247 (44.9%) cases with NTS serovar 
and antimicrobial susceptibility data. Patients infected with Salmonella Typhimurium were 
more likely to die compared with other serovars on univariate analysis (P = .006); this was 
not significant on multivariable analysis (Table 2). Death rates were not significantly higher 
in those patients who had multidrug-resistant isolates.
Where HIV status was known, 39 of 70 (55.7%) HIV-infected patients had meningitis due to 
Salmonella Typhimurium, compared with 31 of 70 (44.3%) HIV-infected patients with NTS 
meningitis due to other serovars, although this was not significant (P = .08).
Multidrug resistance (defined above) was detected in 103 of 247 (41.7%) of the isolates; 56 
of 247 (22.7%) were resistant or intermediately resistant to ciprofloxacin (Table 3). 
Salmonella enterica serovar Isangi and serovar Virchow isolates were more likely to be 
extended-spectrum β-lactamase producers than other serovars (20/30 [66.7%] for Salmonella 
Isangi and Salmonella Virchow vs 17/247 [6.9%] for other serovars; OR, 46.1; 95% CI, 
15.4–138.3). Salmonella Typhimurium was more likely to be multidrug resistant than other 
serovars (62/104 [59.6%] vs 34/143 [23.8%] for other serovars; OR, 4.7; 95% CI, 2.7–8.2; P 
< .001).
MLST of Salmonella Typhimurium
Ninety-seven of 104 Salmonella Typhimurium isolates (93.3%) were MLST subtyped 
(Table 4). There was a trend toward association of outcome with meningitis due to 
Salmonella Typhimurium ST313 on univariate analysis (P = .056; Table 2). HIV-infected 
patients were significantly more likely to be infected by Salmonella Typhimurium ST313 (P 
= .03) compared with other sequence types (Table 4). Salmonella Typhimurium ST16 and 
ST302 were isolated from HIV-uninfected patients.
Multidrug resistance was significantly associated with Salmonella Typhimurium ST313 
(48/65 [73.8%]) compared with Salmonella Typhimurium ST19 (9/30 [30.0%]) (OR, 6.6; 
95% CI, 2.5–17.2; P < .001).
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To our knowledge, this is the largest series of Salmonella meningitis described. Molyneux et 
al [2] described a large series in children aged 2 months to 16 years in Malawi. Predisposing 
conditions in Malawi included HIV infection and malaria [2]. An earlier publication has 
highlighted NTS as a cause of meningitis in HIV-infected South African adult patients and 
described the associated characteristics [7], NTS meningitis representing approximately 
1.3% of all-cause meningitis in this age group [15]. Previously, we have compared South 
African and Malawian data, reviewing the role of NTS in invasive disease in these 2 
countries. The countries both showed a bimodal age distribution, with disease occurring 
primarily in young children and adults aged 20–50 years, confirming the importance of these 
ages in association with invasive disease due to NTS [31].
Our report again highlights the vulnerability of children aged <5 years to NTS meningitis. 
All the adults in our series and 58% of children <5 years of age were HIV infected, although 
none had malaria. A similar distribution in patients’ ages occurs with invasive shigellosis in 
South Africa, with excessive case numbers occurring in the very young and a second peak 
from early adulthood [30].
In addition to our series, the strong association of NTS meningitis with HIV infection in 
adults is suggested by case reports in the literature [18–20, 32]. Predisposing conditions, 
which we did not observe, include autoimmune conditions or other coinfections [21–23]; 
rarely, patients may have no predisposing conditions [24].
In the follow-up of the Malawian pediatric meningitis cases, impaired consciousness was 
significant in the outcome of cases of NTS meningitis [1]. We had similar findings in adults 
and children. Patients presenting with a GCS ≤13 were at a greater risk of death, irrespective 
of HIV status. Of note, none of the HIV-uninfected patients who had a recorded GCS >13 
died. Previous reports from South Africa on meningitis due to N. meningitidis and S. 
pneumoniae emphasize the significance of severity of illness at presentation [3, 4].
Death rates in children in our series were lower than those described in the Malawian series 
[1, 2]; almost half of the deaths were in adults. Wall et al reviewed meningitis due to all 
causes in adolescents and adults in Malawi and similarly found that GCS was the strongest 
independent predictor of mortality, using a cutoff of 11 rather than 13 [5].
Irrespective of age, HIV infection was a major contributing factor for death in the univariate 
model. In South Africa, excessive deaths due to meningococcal and pneumococcal 
meningitis in association with HIV infection have been reported [3, 4], emphasizing the 
vulnerability of these patients to severe infections. In Malawian adults, mortality due to 
bacterial meningitis increased over time [5, 6]: we did not follow patients after discharge, 
but longer hospital stay was associated with improved survival in our series.
Antiretroviral therapy did not impact mortality in this study, stressing the importance of 
early diagnosis and treatment of NTS meningitis. Our patients also received appropriate 
antimicrobial therapy; incorrect treatment did not play a major role in the outcome. We 
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postulated that other comorbidities may have contributed to the development of NTS 
meningitis, but data were too scanty to develop definitive conclusions.
Neonates and young children are particularly vulnerable groups warranting further 
consideration. We did not have access to information posthospitalization, but the Malawian 
study suggested that infants and young children who recover from the acute infection are 
susceptible to neurological sequelae [1, 2]. Although mortality was independent of HIV 
status in our series, a greater proportion of infants who acquired NTS meningitis were HIV 
exposed at birth. Absence of maternal immunity in HIV-infected mothers may increase the 
risk in infants to acquiring NTS meningitis, which should be included in the differential 
diagnosis of causes of neonatal and infant meningitis in settings of high HIV seroprevalence 
[13, 33–36]. Previously, we described the role of childhood Shigella infections predisposing 
HIV-infected women to invasive shigellosis [30]. In this instance, the reverse appears to be 
true: Maternal HIV infection may predispose neonates to invasive salmonellosis, confirming 
the importance of maternal health and a competent immune system in decreasing infant 
mortality in South Africa [37].
In immunosuppressed patients, whether due to HIV infection or extreme youth, innate 
characteristics of Salmonella may predispose the organism to invading the central nervous 
system. Salmonella Typhimurium has the ability to adhere to, penetrate, and invade the 
brain microvascular endothelium, in association with a proinflammatory immune response 
[38]. Our understanding of the organism may need to be altered to adapt to new 
management paradigms; following the introduction of new vaccines to prevent childhood 
meningitis, new pathogens associated with meningitis may be seen to emerge [9, 12, 13].
Salmonella serovar was a better predictor of outcome than multidrug resistance: Salmonella 
Typhimurium was more highly associated with death. Salmonella Typhimurium ST313 is 
well associated with HIV [27]; we found that the organism contributes significantly to NTS 
meningitis in HIV-infected patients. Besides ST313, representing 67% of typed Salmonella 
Typhimurium isolates, ST19 represented 31% of typed isolates; ST19 is commonly 
described worldwide, including from South Africa [39]. A stronger association between HIV 
infection and Salmonella meningitis due to Salmonella Typhimurium ST313, compared with 
Salmonella Typhimurium ST19, was noted. In our previous report of predominantly 
noninvasive Salmonella Typhimurium ST19 infection, most of the patients were HIV 
uninfected [39].
To prevent NTS meningitis infections, further studies are needed regarding the source of 
infections in South Africa. We demonstrated that nosocomial NTS meningitis was rare; 
infections were likely community acquired. Salmonella are ubiquitous, and the association 
between foodborne disease transmission and human-to-human transmission with invasive 
disease is recognized [24, 40, 41]; although transmission is often assumed to be foodborne, 
actual routes are not always clear. Attention should be paid to preventing mother-to-child 
transmission, including maternal screening for fecal pathogens, and ensuring maternal health 
in a potentially disadvantaged subset of HIV-infected individuals [37, 42–45].
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This study had limitations. Clinical data were collected at selected sites only and may not be 
relevant to all the cases, and clinical data were often incomplete. Not all patients at enhanced 
sites had outcome data, HIV results, CD4+ counts, and access to ARV treatment. Data on 
tuberculous meningitis, prior treatment for cryptococcal meningitis, or acute bacterial 
meningitis were not collected. Insufficient data were collected on maternal HIV status in 
pediatric cases, and this impact could not be fully assessed. Fecal cultures were not 
performed on the mothers of infants in association with meningitis; we cannot comment on 
whether maternal carriage of NTS contributed to infection in infants. Incomplete clinical 
data meant that the ubiquity and consequences of Salmonella Typhimurium ST313 in NTS 
meningitis could not be fully elucidated. We elected not to do imputations for the missing 
data, believing that on univariate analysis at least, sufficient association was shown between 
outcome, age, HIV status, GCS, Salmonella Typhimurium, and Salmonella Typhimurium 
sequence types to highlight critical factors associated with Salmonella meningitis. 
Considering the high proportion of missing data in our data set, imputation (especially of 
binary data) could lead to biased inference. The complete case analysis that was conducted 
in this study assumes that data are missing completely at random. Our data may not be 
missing completely at random—but rather missing at random where relevant information 
regarding outcome, HIV result, or consent at a sentinel site was not collected—or not 
missing at random: Sentinel hospitals are typically referral hospitals where HIV-infected 
persons may preferentially present. We do believe we identified the majority of NTS 
meningitis cases over the period; typically in South Africa, patients with suspected 
meningitis will have lumbar punctures performed and CSF samples submitted to the 
laboratory for culture.
In conclusion, we describe a national series of laboratory-confirmed meningitis cases due to 
NTS over an 11-year period, highlighting the importance of disease severity as measured by 
GCS, HIV status in adults, and infection in neonates and infants, and the association of 
outcome and HIV status with specific serovars and sequence types. Early diagnosis and 
appropriate therapy may decrease death rates, and optimizing maternal health may lower 
case numbers in neonates and infants. Better understanding of the role of Salmonella 
Typhimurium, specifically Salmonella Typhimurium ST313, may also assist in controlling 
invasive disease due to NTS.
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Patients with nontyphoidal Salmonella (NTS) meningitis identified in South Africa, 2003–
2013. *Invasive disease was defined as the isolation of NTS from a normally sterile body 
site. Abbreviations: HIV, human immunodeficiency virus; ST, sequence type.
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A, Number of cases of nontyphoidal Salmonella (NTS) meningitis (n = 256) by age group, 
2003–2013. B, Number of cases of NTS meningitis (n = 111) by age group and mortality, 
2003–2013. One patient who recovered did not have an age recorded. C, Number of cases of 
NTS meningitis (n = 91) by age group and human immunodeficiency virus (HIV) status, 
2003–2013. One HIV-infected patient did not have an age recorded.
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Table 1
Clinical Characteristics Associated With Patients With Salmonella Meningitis in South Africa, 2003–2013
Characteristic
Outcome
Total,a No. (%) P ValueSurvived, No. (%) Died, No. (%)
Data from all cases 278 (100)
Age
 <2 mo 11 (26.2) 7 (16.7) 42 (16.4) …
 2 mo to <1 y 26 (30.9) 12 (14.3) 84 (32.8) .5
 1–4 y 2 (22.2) 0 (0.0) 9 (3.5) .2
 5–14 y … … 4 (1.6) …
 15–24 y 2 (25.0) 1 (12.5) 8 (3.1) .9
 25–34 y 8 (18.2) 16 (36.4) 44 (17.2) .07
 35–44 y 7 (17.5) 14 (35.0) 40 (15.6) .08
 >44 y 2 (8.0) 3 (12.0) 25 (9.8) .4
Sex
 Female 20 (17.2) 26 (22.4) 116 (43.4) …
 Male 37 (24.5) 26 (17.2) 151 (56.6) .1
Sentinel site data 59 (52.7) 53 (47.3) 112 (52.5)
HIV status
 Uninfected 17 (77.3) 3 (13.6) 22 (23.9) …
 Infected 32 (45.7) 30 (42.9) 70 (76.1) .008
Glasgow Coma Scale
 ≤13 2 (20.0) 8 (80.0) 10 (23.3) …
 >13 27 (81.8) 5 (15.2) 33 (76.7) .3
Nosocomial infection
 No 52 (51.5) 45 (44.6) 101 (88.6) …
 Yes 6 (46.2) 6 (46.2) 13 (11.4) .8
Cotrimoxazole prophylaxis
 No 40 (65.6) 20 (32.8) 61 (75.3) …
 Yes 10 (50.0) 9 (45.0) 20 (24.7) .3
Antiretrovirals
 No 31 (57.4) 22 (40.7) 54 (78.3) …
 Yes 9 (60.0) 5 (33.3) 15 (21.7) .7
CD4 count, cells/μL
 ≤200 10 (34.5) 16 (55.2) 29 (87.9) …
 >200 2 (50.0) 2 (50.0) 4 (12.1) .7
Other comorbidity
 No 40 (50.6) 29 (25.3) 79 (63.7) …
 Yes 19 (42.2) 24 (53.3) 45 (36.3) .2
Salmonella serotype
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Characteristic
Outcome
Total,a No. (%) P ValueSurvived, No. (%) Died, No. (%)
 Enteritidis 21 (55.3) 12 (31.6) 38 (26.0) …
 Typhimurium 17 (27.4) 29 (46.8) 62 (42.5) .02
 Other 21 (45.7) 12 (26.1) 46 (31.5) .2
Salmonella multidrug resistance
 No 40 (46.5) 27 (31.4) 86 (63.7) …
 Yes 16 (32.7) 22 (44.9) 49 (36.3) .08
Salmonella Typhimurium sequence type
 ST19 6 (35.3) 4 (23.5) 17 (30.9) …
 ST313 8 (21.1) 23 (60.5) 38 (69.1) .05
Abbreviations: HIV, human immunodeficiency virus; ST, sequence type.
a
Total includes those patients for whom outcome was unknown.
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Table 4
Association of Salmonella Typhimurium Multilocus Sequence Type, Human Immunodeficiency Virus 
Infection, and Multidrug Resistance (Resistance to ≥3 Antimicrobials)
Salmonella Typhimurium 
Sequence Type (n = 97)
HIV-Uninfected 
Patients (n = 7)
HIV-Infected 
Patients (n = 38)
Nonresistant Isolates 
or Isolates With 
Limited Resistance Multidrug-Resistant Isolatesa
16 (n = 1) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
19 (n = 30) 4 (28.6) 10 (71.4) 21 (70.0) 9 (30.0)
302 (n = 1) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
313 (n = 65) 1 (3.4) 28 (96.6) 17 (26.1) 48 (73.8)
Data are presented as No. (%).
Abbreviation: HIV, human immunodeficiency virus.
a
Includes intermediate resistance.
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